|
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
NCT ID : 05191017
Protocol Number : EIR_NUV-422-04
Phase : 1b/2
Location : Santa Monica, Ca
|
Urology and Urologic Oncology
|
Rebecca Gross, M.D.
|
|
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT ID : 05608291
Protocol Number : R3767-ONC-2055
Phase : 3
Location : Saint John's Cancer Institute
|
Melanoma, Skin and Soft Tissue Tumors
|
Kim Margolin, M.D.
|
|
A Beta-only IL-2 Immunotherapy Study (ABILITY-1)
NCT ID : 05086692
Protocol Number : MDNA 11-01
Phase : 1/2
Location : Saint John's Cancer Institute
|
All Solid Tumors
|
Przemyslaw Twardowski, M.D.
|
|
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)
NCT ID : 04658862
Protocol Number : 17000139BLC3001 (Sunshine 2)
Phase : 3
Location : Saint John's Cancer Institute
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
A Study of ARV-766 Given by Mouth in Men With Metastatic Castration-resistant Prostate Cancer Who Have Progressed on Prior Approved Systemic Therapies
NCT ID : 05067140
Protocol Number : ARV-766mCRPC-101
Phase : 1/2
Location : Saint John's Cancer Institute
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
NCT ID : 03972657
Protocol Number : R5678-ONC-1879
Phase : 1/2
Location : Saint John's Cancer Institute
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT ID : 05812807
Protocol Number : A012103
Phase : 3
Location : Saint John's Cancer Institute
|
Breast Surgery and Oncology
|
Parvin Peddi, M.D.
|
|
(SPARTA) APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT ID : 03175224
Protocol Number : SPARTA APL-101
Phase : 2
Location : Saint John's Cancer Institute
|
All Solid Tumors
|
Akanksha Sharma, M.D.
|
|
A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors)
NCT ID : 05155332
Protocol Number : 1456-0001
Phase : 1
Location : Saint John's Cancer Institute
|
All Solid Tumors
|
Naveed Wagle, M.D.
|
|
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION)
NCT ID : 05580562
Protocol Number : ONC201-108
Phase : 3
Location : Saint John's Cancer Institute
|
Brain Tumors & Neuroscience
|
Akanksha Sharma, M.D.
|
|
Known Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions
NCT ID : 05068726
Protocol Number : GE-280-401
Phase : 4
Location : Saint John's Cancer Institute
|
Breast Surgery and Oncology
|
Parvin Peddi, M.D.
|
|
Metastatic Castration-Resistant Prostate Cancer (Curium)
NCT ID : 05204927
Protocol Number : CURLu177PSM0001
Phase : 3
Location : Santa Monica, Ca
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
Metastatic Castration-Resistant Prostate Cancer (CAPItello-280)
NCT ID : 05348577
Protocol Number : D361EC00001 (CAPItello-280)
Phase : 3
Location : Santa Monica, Ca
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
Locally advanced or metastatic solid tumors: A Phase I Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Subjects with Advanced Cancer
NCT ID : 03860272
Protocol Number : C-800-01
Phase : 1
Location : Santa Monica, CA
|
All Solid Tumors Multiple Tumors
|
Kim Margolin, M.D.
|
|
Melanoma, Merkel Cell, Renal Cell NSCLC (iPREDICT)
NCT ID : 05013099
Protocol Number : IAB-CD8-203
Phase : 2b
Location : Santa Monica, CA
|
All Solid Tumors
|
Kim Margolin, M.D.
|
|
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (IORT)
NCT ID : 04681677
Protocol Number : CTPR-0017 GLIOX
Phase : 2
Location : Santa Monica, Ca
|
Brain Tumors & Neuroscience
|
Naveed Wagle, M.D.
|
|
Biomarker Low Risk Node Positive Breast Cancer: TAILOR RT.
NCT ID : 03488693
Protocol Number : CCTGMA.39
Phase : 3
Location : Santa Monica, CA
|
Breast Surgery and Oncology
|
Janie Grumley, M.D.
|
|
All Solid Metastatic or Advanced Tumors: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
NCT ID : 04246671
Protocol Number : TAEK-VAC-HerBy-001
Phase : 1
Location : Saint John's Cancer Institute
|
All Solid Tumors
|
Naveed Wagle, M.D.
|
|
(TRIDENT) Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With Radiation Therapy Temozolomide for the Treatment of Newly Diagnosed GBM (EF-32)
NCT ID : 04471844
Protocol Number : EF-32 Trident
Phase : 3
Location : Saint John's Cancer Institute
|
Brain Tumors & Neuroscience
|
Akanksha Sharma, M.D.
|
|
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (WHO Grade IV)
NCT ID : 04762069
Protocol Number : CNS-201
Phase : 2
Location : Saint John's Cancer Institute
|
Brain Tumors & Neuroscience
|
Naveed Wagle, M.D.
|
|
Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT ID : 04958785
Protocol Number : GS-US-586-6144
Phase : 2
Location : Saint John's Cancer Institute
|
Breast Surgery and Oncology
|
Parvin Peddi, M.D.
|
|
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
NCT ID : 05568472
Protocol Number : SWOG-S2010
Phase : 3
Location : Saint John's Cancer Institute
|
Breast Surgery and Oncology
|
Janie Grumley, M.D.
|
|
White Button Mushroom Supplement for Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Naïve Patients
NCT ID : 04519879
Protocol Number : White Button Mushroom
Phase : 2
Location : Santa Monica, CA
|
Urology and Urologic Oncology
|
Przemyslaw Twardowski, M.D.
|
|
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
NCT ID : 04566393
Protocol Number : ULI-EAP-100
Phase : N/A
Location : Santa Monica, CA
|
Multiple Tumors
|
Naveed Wagle, M.D.
|
|
Intermediate-size Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
NCT ID : 04617002
Protocol Number : ONC028
Phase : N/A
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Akanksha Sharma, M.D.
|
|
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma
NCT ID : 04388475
Protocol Number : OKN-007-OL
Phase : 1
Location : Saint John's Cancer Institute
|
Brain Tumors & Neuroscience
|
Naveed Wagle, M.D.
|
|
Evaluating the Clinical Efficacy of an Early-Stage Lung Cancer Detector
NCT ID : N/A
Protocol Number : CPC001-2017-S5P4-PSJHC
Phase : N/A
Location : Santa Monica, CA
|
Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Robert McKenna, M.D.
|
|
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)
NCT ID : N/A
Protocol Number : CBI_2019_SLNBprosp_001
Phase : N/A
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Richard Essner, M.D.
|
|
Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System In the Treatment of Subacute and Chronic Subdural Hematoma (EMBOLISE)
NCT ID : 04402632
Protocol Number : MDT19027ONYX
Phase : N/A
Location : Providence Little Company of Mary Medical Center: 4101 Torrance Blvd, Torrance, CA
|
Clinical Trials Stroke and Neurovascular Research Translational Neurosciences
|
Jason Tarpley, M.D. & Walavan Sivakumar, M.D.
|
|
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Rrial (1-BETTER) Examining XB2001 (anti-IL-1⍺ True Human antibody) in Combination with ONIVYDE + 5-FU/LV (+folinic acid) in Advanced Pancreatic Cancer
NCT ID : 04825288
Protocol Number : 2020-PT049
Phase : 3
Location : Disney Family Cancer Center
|
Gastrointestinal and Hepatobiliary Tumors
|
Karlton Wong, M.D.
|
|
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)
NCT ID : 04873362
Protocol Number : WO42633
Phase : 3
Location : Disney Family Cancer Center
|
Breast Surgery and Oncology
|
Erwin Grussie, M.D.
|
|
Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)
NCT ID : 05267106
Protocol Number : INCB 54828-209
Phase : 2
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Akanksha Sharma, M.D.
|
